Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Archive

Cell Cure Neurosciences Receives Grant of $1.33 Million From Israel's Office of the Chief Scientist

Cell Cure Neurosciences Ltd., whose Chief Scientific Officer is Hadassah University Medical Center's Prof. Benjamin Reubinoff--Director of the its Human Embryonic Stem Cell Research Center--received a 1.3 million-dollar grant from Israel's Office of the Chief Scientist (OCS) to help finance its development of a treatment for age-related macular degeneration (AMD).

Cell Cure, established in 2005, manufactures diverse cell products, sourced from clinical-grade human embryonic stem cells. Its current programs include developing cells for the treatment of macular degeneration, Parkinson's disease, and cells potentially useful in treating multiple sclerosis. Cell Cure's plan for its cell-based product, OpRegen(R) includes filing an application to commence human clinical trials in 2013.

"We wish to thank the Office of the Chief Scientist for their participation in advancing this important new application of regenerative medicine," said Charles Irving, Chief Executive of Cell Cure. "We anticipate that OpRegen(R) will make a real difference in the quality of life of the aging population in many industrialized countries," he noted, "and hence it is a strategic investment for not only Israel, but the world as a whole."

AMD is a severe form of acute vision loss and the leading cause of blindness in older people. It affects that part of the retina which is most critical in everyday tasks, such as reading and recognizing faces. "I join with Dr. Irving in thanking OCS for its generous support in accelerating these advances in stem cell biology into the clinic," said Prof. Reubinoff.

Date: 8/8/2012


More hMedicine Stories




Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America